532 related articles for article (PubMed ID: 34987087)
1. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract][Full Text] [Related]
2. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
3. EGFR signaling in breast cancer: bad to the bone.
Foley J; Nickerson NK; Nam S; Allen KT; Gilmore JL; Nephew KP; Riese DJ
Semin Cell Dev Biol; 2010 Dec; 21(9):951-60. PubMed ID: 20813200
[TBL] [Abstract][Full Text] [Related]
4. The role of ErbB4 in cancer.
Segers VFM; Dugaucquier L; Feyen E; Shakeri H; De Keulenaer GW
Cell Oncol (Dordr); 2020 Jun; 43(3):335-352. PubMed ID: 32219702
[TBL] [Abstract][Full Text] [Related]
5. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.
Mill CP; Gettinger KL; Riese DJ
Exp Cell Res; 2011 Feb; 317(4):392-404. PubMed ID: 21110957
[TBL] [Abstract][Full Text] [Related]
6. Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.
Gallo RM; Bryant IN; Mill CP; Kaverman S; Riese DJ
J Cancer Res Ther Oncol; 2013 Aug; 1(1):10. PubMed ID: 24791013
[TBL] [Abstract][Full Text] [Related]
7. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities.
Penington DJ; Bryant I; Riese DJ
Cell Growth Differ; 2002 Jun; 13(6):247-56. PubMed ID: 12114214
[TBL] [Abstract][Full Text] [Related]
8. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
9. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.
Williams EE; Trout LJ; Gallo RM; Pitfield SE; Bryant I; Penington DJ; Riese DJ
Cancer Lett; 2003 Mar; 192(1):67-74. PubMed ID: 12637154
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutations of the ERBB4 kinase domain in human cancers.
Soung YH; Lee JW; Kim SY; Wang YP; Jo KH; Moon SW; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
Int J Cancer; 2006 Mar; 118(6):1426-9. PubMed ID: 16187281
[TBL] [Abstract][Full Text] [Related]
11. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
[TBL] [Abstract][Full Text] [Related]
12. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas.
Silva SD; Cunha IW; Younes RN; Soares FA; Kowalski LP; Graner E
Oral Dis; 2010 Nov; 16(8):774-80. PubMed ID: 20604875
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
14. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
[TBL] [Abstract][Full Text] [Related]
15. ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma.
Liu S; Geng R; Lin E; Zhao P; Chen Y
Front Genet; 2021; 12():602160. PubMed ID: 33732282
[TBL] [Abstract][Full Text] [Related]
16. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
17. Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy.
Patnaik SK; Swaroop AK; Nagarjuna P; Nanjan MJ; Chandrasekar MJN
Curr Mol Pharmacol; 2024; 17(1):e240223214012. PubMed ID: 36843255
[TBL] [Abstract][Full Text] [Related]
18. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
[TBL] [Abstract][Full Text] [Related]
19. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
